Diagnostic and prognostic value of ferroptosis-related genes in patients with Myelodysplastic neoplasms

References

• Cazzola M. Myelodysplastic syndromes. N Engl J Med. 2020;383(14):1358–1374.
   PubMed Web of Science ®Google Scholar
• [Fenaux] Haase P, Santini D, Sanz V, et al. Myelodysplastic syndromes: ESMO clinical practice guidelines for diagnosis, treatment and follow-up(dagger). Ann Oncol: Official J Eur Soc Med Oncol. 2021;32(2):142–156. doi:10.1016/j.annonc.2020.11.002
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Chien KS, Montalban-Bravo G. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management. Am J Hematol. 2020;95(11):1399–1420.
   PubMed Web of Science ®Google Scholar
• Kennedy AL, Shimamura A. Genetic predisposition to MDS: clinical features and clonal evolution. Blood. 2019;133(10):1071–1085. doi:10.1182/blood-2018-10-844662
   PubMed Web of Science ®Google Scholar
• Huber S, Haferlach T, Meggendorfer M, et al. SF3B1 mutated MDS: blast count, genetic co-abnormalities and their impact on classification and prognosis. Leukemia. 2022;36(12):2894–2902.
   PubMedGoogle Scholar
• Duncavage EJ, Bagg A, Hasserjian RP, et al. Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia. Blood. 2022;140(21):2228–2247. doi:10.1182/blood.2022015853
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Shallis RM, Wang R, et al. Epidemiology of myelodysplastic syndromes: why characterizing the beast is a prerequisite to taming it. Blood Rev. 2019;34:1–15. doi:10.1016/j.blre.2018.09.001
   PubMed Web of Science ®Google Scholar
• Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–1072. doi:10.1016/j.cell.2012.03.042
   PubMed Web of Science ®Google Scholar
• Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22(4):266–282. doi:10.1038/s41580-020-00324-8
   PubMed Web of Science ®Google Scholar
• Lee H, Zandkarimi F, Zhang Y, et al. Energy-stress-mediated AMPK activation inhibits ferroptosis. Nat Cell Biol. 2020;22(2):225–234. doi:10.1038/s41556-020-0461-8
   PubMed Web of Science ®Google Scholar
• Lei G, Zhuang L, Gan B. Targeting ferroptosis as a vulnerability in cancer. Nat Rev Cancer. 2022;22(7):381–396. doi:10.1038/s41568-022-00459-0
   PubMed Web of Science ®Google Scholar
• Yusuf RZ, Saez B, Sharda A, et al. Aldehyde dehydrogenase 3a2 protects AML cells from oxidative death and the synthetic lethality of ferroptosis inducers. Blood. 2020;136(11):1303–1316. doi:10.1182/blood.2019001808
   PubMed Web of Science ®Google Scholar
• [Chu] B, Kon N, Chen D, et al. ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway. Nat Cell Biol. 2019;21(5):579–591. doi:10.1038/s41556-019-0305-6
   PubMed Web of Science ®Google Scholar
• Lv Q, Niu H;, Yue L, et al. Abnormal ferroptosis in myelodysplastic syndrome. Front Oncol. 2020;10:1656.
   PubMed Web of Science ®Google Scholar
• Stockwell BR, Jiang X. A Physiological function for ferroptosis in tumor suppression by the immune system. Cell Metab. 2019;30(1):14–15. doi:10.1016/j.cmet.2019.06.012
   PubMed Web of Science ®Google Scholar
• Liao P, Wang W, Wang W, et al. CD8(+) T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4. Cancer Cell. 2022;40(4):365–378 e6. doi:10.1016/j.ccell.2022.02.003
   PubMed Web of Science ®Google Scholar
• Winter S, Shoaie S, Kordasti S, et al. Integrating the “immunome” in the stratification of myelodysplastic syndromes and future clinical trial design. J Clin Oncol. 2020;38(15):1723–1735.
   PubMed Web of Science ®Google Scholar
• Giovazzino A, Leone S, Rubino V, et al. Reduced regulatory T cells (Treg) in bone marrow preferentially associate with the expansion of cytotoxic T lymphocytes in low risk MDS patients. Br J Haematol. 2018;185(2):357–360.
   PubMed Web of Science ®Google Scholar
• Kordasti SY, Ingram W, Hayden J, et al. CD4+CD25high Foxp3 + regulatory T cells in myelodysplastic syndrome (MDS). Blood. 2007;110(3):847–850.
   PubMed Web of Science ®Google Scholar
• Xu C, Sun S, Johnson T, et al. The glutathione peroxidase Gpx4 prevents lipid peroxidation and ferroptosis to sustain Treg cell activation and suppression of antitumor immunity. Cell Rep. 2021;35(11):109235. doi:10.1016/j.celrep.2021.109235
   PubMed Web of Science ®Google Scholar
• [Weber] S, Parmon A, Kurrle N, et al. The clinical significance of Iron overload and iron metabolism in myelodysplastic syndrome and acute myeloid leukemia. Front Immunol. 2020;11:627662.
   PubMed Web of Science ®Google Scholar
• Franke GN, Kubasch AS, Cross M, et al. Iron overload and its impact on outcome of patients with hematological diseases. Mol Aspects Med. 2020;75:100868. doi:10.1016/j.mam.2020.100868
   PubMed Web of Science ®Google Scholar
• Geng S, Xu R, Huang X, et al. Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment. Front Immunol. 2022;13:950134. doi:10.3389/fimmu.2022.950134
   PubMed Web of Science ®Google Scholar
• Saygin C, Carraway HE. Current and emerging strategies for management of myelodysplastic syndromes. Blood Rev. 2021;48:100791. doi:10.1016/j.blre.2020.100791
   PubMed Web of Science ®Google Scholar
• Scalzulli E, Pepe S, Colafigli G, et al. Therapeutic strategies in low and high-risk MDS: what does the future have to offer? Blood Rev. 2021;45:100689. doi:10.1016/j.blre.2020.100689
   PubMed Web of Science ®Google Scholar
• Huang X, Liang X, Zhu S, et al. Expression and clinical significance of RAG1 in myelodysplastic syndromes. Hematology. 2022;27(1):1122–1129. doi:10.1080/16078454.2022.2127462
   PubMed Web of Science ®Google Scholar
• Shenoy N, Vallumsetla N, Rachmilewitz E, et al. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome. Blood. 2014;124(6):873–881. doi:10.1182/blood-2014-03-563221
   PubMed Web of Science ®Google Scholar
• Siamoglou S, Boers R, Koromina M, et al. Genome-wide analysis toward the epigenetic aetiology of myelodysplastic syndrome disease progression and pharmacoepigenomic basis of hypomethylating agents drug treatment response. Hum Genomics. 2023;17(1):37. doi:10.1186/s40246-023-00483-7
   PubMed Web of Science ®Google Scholar
• Preudhomme C, Quesnel B, Vachee A, et al. Absence of amplification of MDM2 gene, a regulator of p53 function, in myelodysplastic syndromes. Leukemia. 1993;7(8):1291–1293.
   PubMed Web of Science ®Google Scholar
• Salomao N, Maslah N, Giulianelli A, et al. Reduced murine double minute 2 and 4 protein, but not messenger RNA, expression is associated with more severe disease in myelodysplastic syndromes and acute myeloblastic leukaemia. Br J Haematol. 2023;201(2):234–248. doi:10.1111/bjh.18608
   PubMed Web of Science ®Google Scholar
• Du Y, Li LL, Chen H, et al. A novel all-trans retinoic acid derivative inhibits proliferation and induces apoptosis of myelodysplastic syndromes cell line SKM-1 cells via up-regulating p53. Int Immunopharmacol. 2018;65:561–570. doi:10.1016/j.intimp.2018.10.041
   PubMed Web of Science ®Google Scholar
• Trowbridge JJ, Starczynowski DT. Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS. J Exp Med. 2021;218(7):e20201544. doi:10.1084/jem.20201544
   PubMed Web of Science ®Google Scholar
• Sallman DA, List A. The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes. Blood. 2019;133(10):1039–1048. doi:10.1182/blood-2018-10-844654
   PubMed Web of Science ®Google Scholar
• Giovazzino A, Leone S, Rubino V, et al. Reduced regulatory T cells (Treg) in bone marrow preferentially associate with the expansion of cytotoxic T lymphocytes in low risk MDS patients. Br J Haematol. 2019;185(2):357–360. doi:10.1111/bjh.15496
   PubMed Web of Science ®Google Scholar
• Yang F, Wu Z, Yang D, et al. Characteristics of macrophages from myelodysplastic syndrome microenvironment. Exp Cell Res. 2021;408(1):112837. doi:10.1016/j.yexcr.2021.112837
   PubMed Web of Science ®Google Scholar